The Aspirant

A better world is possible

The Ozempic Ghost: Corporate Profit at the Cost of Human Life #

Tuesday, 17 March 2026 · words

A sterile, high-contrast shot of a laboratory shelf filled with identical white medicine bottles. One bottle has fallen over, its contents spilling out onto a cold, metallic surface. The framing is tight and geometric, focusing on the repetition and the clinical coldness of the scene.
A sterile, high-contrast shot of a laboratory shelf filled with identical white medicine bottles. One bottle has fallen over, its contents spilling out onto a cold, metallic surface. The framing is tight and geometric, focusing on the repetition and the clinical coldness of the scene.

The 'miracle' of GLP-1 weight-loss drugs like Ozempic and Wegovy is curdling into a nightmare for thousands of patients. More than 4,000 Americans have filed lawsuits against pharmaceutical giant Novo Nordisk, alleging the company failed to report life-changing side effects, including permanent eye damage (NAION), and even deaths. The FDA has recently issued a warning letter to the company for failing to report suicides and fatalities potentially linked to the drugs. This is the standard operating procedure of 'Big Pharma': rush a product to market to capitalize on a socially-engineered crisis of body image, then bury the data when the bodies start piling up.

While the wealthy use these drugs for 'neural protection' and vanity, the working class is being treated as a laboratory for unvetted chemical intervention. The cost of these 'miracles' is often thousands of dollars per month, an extraction of wealth that targets the most vulnerable. When we see 'non-responders' blaming themselves for the drug’s failure, we see the ultimate success of corporate gaslighting. We must move toward a healthcare model that prioritizes public safety and preventative health over the quarterly earnings of drug manufacturers. Medical breakthroughs must be public goods, not profit centers.